DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02772614 (ClinicalTrials.gov)	January 2006	12/5/2016	Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites	An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral Administration	Parkinson's Disease	Drug: BIA 3-202 (200 mg)	Bial - Portela C S.A.	NULL	Completed	40 Years	55 Years	Male	4	Phase 1	Switzerland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02772614
(ClinicalTrials.gov)

January 2006

12/5/2016

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral Administration

Parkinson's Disease

Drug: BIA 3-202 (200 mg)

Bial - Portela C S.A.

NULL

Completed

40 Years

55 Years

Male

Phase 1

Switzerland